Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

125.34 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
5 Analysts Have This to Say About Sarepta Therapeutics
Via Benzinga
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
An upcoming data readout could fuel another rally in the biotech's shares. 
Via The Motley Fool
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sarepta Therapeutics Stock Showing Rising Relative Strength
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Earnings Preview: Sarepta Therapeutics
Via Benzinga
2 Biotech Growth Stocks I'd Buy Right Now
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
Where Sarepta Therapeutics Stands With Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Top Growth Stocks to Buy With $500
No need to break the bank to invest in stocks. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Helping save and improve patients' lives in novel ways can be a lucrative activity. 
Via The Motley Fool
What 25 Analyst Ratings Have To Say About Sarepta Therapeutics
Via Benzinga
Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades. 
Via Benzinga
$3M Bet On Tidewater? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2023. 
Via The Motley Fool
3 Biotech Stocks to Sell Before They Damage Your Portfolio
With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point. 
Via InvestorPlace
Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%?
While its gene therapy for Duchenne muscular dystrophy has been conditionally approved, it'll take a while to prove its merit. 
Via The Motley Fool
Why CarMax Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023
Via Benzinga
Canopy Growth, Avadel Pharmaceuticals And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Friday. Here are some big stocks recording losses in today’s session. GSR II Meteora Acquisition Corp. (NASDAQ: GSRM)... 
Via Benzinga
Sarepta Therapeutics' Therapy Becomes First To Score FDA Nod For Duchenne Muscular Dystrophy Gene Therapy
The FDA has granted accelerated approval to closely watched Sarepta Therapeutics Inc's (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback